Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitals, Pediatric | 2 | 2024 | 115 | 1.030 |
Why?
|
| Tertiary Care Centers | 3 | 2024 | 106 | 0.990 |
Why?
|
| Syphilis, Congenital | 1 | 2024 | 6 | 0.970 |
Why?
|
| Bacteremia | 3 | 2022 | 102 | 0.930 |
Why?
|
| Clostridium Infections | 3 | 2023 | 124 | 0.880 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 14 | 0.820 |
Why?
|
| Hypotension | 1 | 2022 | 71 | 0.790 |
Why?
|
| Publishing | 1 | 2022 | 90 | 0.770 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 270 | 0.760 |
Why?
|
| Public Health | 1 | 2022 | 138 | 0.760 |
Why?
|
| Fever | 5 | 2022 | 128 | 0.690 |
Why?
|
| Pandemics | 2 | 2022 | 771 | 0.630 |
Why?
|
| Sepsis | 1 | 2022 | 319 | 0.620 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 69 | 0.600 |
Why?
|
| Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.580 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2019 | 27 | 0.550 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 276 | 0.550 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 78 | 0.530 |
Why?
|
| Neutrophils | 3 | 2020 | 308 | 0.470 |
Why?
|
| Child | 12 | 2023 | 7154 | 0.440 |
Why?
|
| Virulence Factors | 2 | 2010 | 112 | 0.420 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2009 | 5 | 0.410 |
Why?
|
| Hemolysin Proteins | 2 | 2009 | 34 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 6 | 2023 | 786 | 0.400 |
Why?
|
| Bacterial Toxins | 2 | 2009 | 114 | 0.380 |
Why?
|
| Infant, Newborn | 4 | 2024 | 2479 | 0.370 |
Why?
|
| Humans | 36 | 2024 | 89157 | 0.360 |
Why?
|
| Adhesins, Bacterial | 1 | 2010 | 36 | 0.360 |
Why?
|
| Bacterial Adhesion | 1 | 2010 | 84 | 0.360 |
Why?
|
| Proteoglycans | 1 | 2010 | 123 | 0.340 |
Why?
|
| Membrane Transport Proteins | 1 | 2010 | 169 | 0.330 |
Why?
|
| Communicable Diseases | 1 | 2010 | 63 | 0.330 |
Why?
|
| Lung Diseases | 2 | 2009 | 269 | 0.330 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 22 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 532 | 0.320 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 28 | 0.320 |
Why?
|
| Actinomycosis | 1 | 2008 | 12 | 0.310 |
Why?
|
| Syndecans | 1 | 2007 | 4 | 0.310 |
Why?
|
| HIV Infections | 1 | 2017 | 837 | 0.300 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 236 | 0.300 |
Why?
|
| Drug Utilization | 2 | 2018 | 65 | 0.290 |
Why?
|
| Guideline Adherence | 2 | 2021 | 229 | 0.290 |
Why?
|
| Critical Care | 2 | 2022 | 380 | 0.280 |
Why?
|
| Neoplasms | 1 | 2022 | 3037 | 0.280 |
Why?
|
| Shock, Septic | 2 | 2023 | 104 | 0.270 |
Why?
|
| Health Personnel | 2 | 2021 | 213 | 0.270 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 155 | 0.270 |
Why?
|
| Adolescent | 9 | 2022 | 9243 | 0.260 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2005 | 1 | 0.260 |
Why?
|
| Paragonimiasis | 1 | 2005 | 1 | 0.260 |
Why?
|
| Appendicitis | 1 | 2006 | 64 | 0.260 |
Why?
|
| Child, Preschool | 10 | 2023 | 3721 | 0.250 |
Why?
|
| Cross Infection | 2 | 2017 | 146 | 0.250 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2024 | 9 | 0.240 |
Why?
|
| Retrospective Studies | 6 | 2024 | 9022 | 0.230 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 643 | 0.230 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 65 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 117 | 0.220 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2023 | 23 | 0.220 |
Why?
|
| Inflammation | 2 | 2008 | 971 | 0.210 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 91 | 0.200 |
Why?
|
| Critical Pathways | 1 | 2022 | 37 | 0.200 |
Why?
|
| Hand Hygiene | 1 | 2021 | 10 | 0.190 |
Why?
|
| Inpatients | 2 | 2021 | 310 | 0.190 |
Why?
|
| Burns | 1 | 2023 | 141 | 0.190 |
Why?
|
| Infliximab | 2 | 2019 | 159 | 0.180 |
Why?
|
| Infection Control | 2 | 2021 | 120 | 0.180 |
Why?
|
| United States | 6 | 2024 | 6965 | 0.170 |
Why?
|
| Male | 13 | 2024 | 42309 | 0.170 |
Why?
|
| Neutropenia | 1 | 2020 | 216 | 0.170 |
Why?
|
| Leadership | 1 | 2021 | 138 | 0.170 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 10 | 0.170 |
Why?
|
| Pregnancy | 2 | 2024 | 3011 | 0.160 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 29 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 38 | 0.160 |
Why?
|
| Syndecan-1 | 2 | 2009 | 16 | 0.160 |
Why?
|
| Expert Testimony | 1 | 2018 | 46 | 0.160 |
Why?
|
| Chagas Disease | 1 | 2018 | 3 | 0.160 |
Why?
|
| Logistic Models | 1 | 2022 | 1213 | 0.160 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 23 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2022 | 346 | 0.150 |
Why?
|
| Leishmaniasis | 1 | 2017 | 4 | 0.150 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 16 | 0.150 |
Why?
|
| Female | 12 | 2024 | 46078 | 0.150 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 46 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 922 | 0.150 |
Why?
|
| Directly Observed Therapy | 1 | 2017 | 5 | 0.150 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 6 | 0.150 |
Why?
|
| Health Resources | 1 | 2018 | 81 | 0.140 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 28 | 0.140 |
Why?
|
| Meglumine | 1 | 2017 | 38 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 435 | 0.140 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 32 | 0.140 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2017 | 26 | 0.140 |
Why?
|
| HIV Antibodies | 1 | 2017 | 26 | 0.140 |
Why?
|
| Drug Overdose | 1 | 2018 | 71 | 0.140 |
Why?
|
| Vancomycin | 1 | 2017 | 73 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 149 | 0.140 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.140 |
Why?
|
| Blood Culture | 1 | 2016 | 10 | 0.140 |
Why?
|
| Sorbitol | 1 | 2016 | 8 | 0.130 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 134 | 0.130 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 8 | 0.130 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 35 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 259 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 841 | 0.120 |
Why?
|
| Social Media | 1 | 2016 | 93 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 151 | 0.120 |
Why?
|
| Genotype | 1 | 2019 | 1848 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 149 | 0.110 |
Why?
|
| Epidermal Cyst | 1 | 2013 | 7 | 0.110 |
Why?
|
| Education, Medical | 1 | 2016 | 243 | 0.110 |
Why?
|
| Meningitis | 1 | 2013 | 20 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 442 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 890 | 0.110 |
Why?
|
| Physician's Role | 1 | 2015 | 177 | 0.110 |
Why?
|
| Escherichia coli | 1 | 2016 | 605 | 0.110 |
Why?
|
| Animals | 7 | 2010 | 27330 | 0.100 |
Why?
|
| Brain Diseases | 1 | 2013 | 185 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2015 | 337 | 0.100 |
Why?
|
| Infant | 4 | 2019 | 3149 | 0.090 |
Why?
|
| Aspirin | 2 | 2014 | 159 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 740 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2014 | 242 | 0.080 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2009 | 21 | 0.080 |
Why?
|
| Chemokines | 1 | 2008 | 74 | 0.080 |
Why?
|
| Lung Injury | 1 | 2009 | 53 | 0.080 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2020 | 104 | 0.080 |
Why?
|
| Enterotoxins | 1 | 2008 | 21 | 0.080 |
Why?
|
| Brain Abscess | 1 | 2007 | 8 | 0.080 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2007 | 21 | 0.080 |
Why?
|
| Adult | 3 | 2023 | 26542 | 0.080 |
Why?
|
| Leishmania | 2 | 2017 | 7 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2010 | 669 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1596 | 0.070 |
Why?
|
| Foreign Bodies | 1 | 2007 | 66 | 0.070 |
Why?
|
| Bronchi | 1 | 2007 | 229 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2658 | 0.070 |
Why?
|
| Risk Factors | 3 | 2023 | 5483 | 0.070 |
Why?
|
| Praziquantel | 1 | 2005 | 1 | 0.070 |
Why?
|
| Anthelmintics | 1 | 2005 | 6 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3211 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 2614 | 0.060 |
Why?
|
| Chicago | 2 | 2019 | 1424 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1215 | 0.060 |
Why?
|
| Radiography | 1 | 2005 | 809 | 0.050 |
Why?
|
| Bandages | 1 | 2023 | 41 | 0.050 |
Why?
|
| Hand Disinfection | 1 | 2021 | 17 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 30 | 0.050 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.050 |
Why?
|
| Mice | 3 | 2009 | 11743 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 223 | 0.040 |
Why?
|
| Critical Illness | 1 | 2023 | 306 | 0.040 |
Why?
|
| Molecular Typing | 1 | 2019 | 17 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 155 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 13 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 53 | 0.040 |
Why?
|
| Medical Audit | 1 | 2018 | 39 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 175 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 232 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 153 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 70 | 0.040 |
Why?
|
| Epidemiologists | 1 | 2017 | 1 | 0.040 |
Why?
|
| Public Health Practice | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 389 | 0.040 |
Why?
|
| Public Health Administration | 1 | 2017 | 18 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 385 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2017 | 65 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 105 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 64 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 122 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 75 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 186 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 6294 | 0.030 |
Why?
|
| Drug Costs | 1 | 2017 | 63 | 0.030 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 682 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 159 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 733 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 868 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 834 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1242 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 299 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 50 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1855 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 876 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 461 | 0.030 |
Why?
|
| Viruses | 1 | 2015 | 78 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 937 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 216 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 144 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 43 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2014 | 190 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2014 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2753 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 711 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2864 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 570 | 0.020 |
Why?
|
| Physicians | 1 | 2018 | 690 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2010 | 92 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1402 | 0.020 |
Why?
|
| Craniotomy | 1 | 2007 | 88 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1012 | 0.020 |
Why?
|
| Drainage | 1 | 2007 | 162 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2007 | 159 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1088 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1574 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 8217 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 802 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 1890 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 1258 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 1990 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1224 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3376 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 25910 | 0.010 |
Why?
|